TheBrief.Health
New evidence supports sequential pembrolizumab after radiotherapy for high-risk Merkel cell carcinoma, reducing disease recurrence, preventing distant metastases, and reshaping multidisciplinary postoperative treatment strategies.
526 episodes
Comments
0Be the first to comment
Sign up now and become a member of the TheBrief.Health community!